SCHEMBL1490441

SCHEMBL1490441

CCOC(=O)c1c(NC(=O)c2ccc(Cl)cc2)csc1-c1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPT P10636 5/20 0.52
THRB P10828 2/20 0.47
PRKCZ Q05513 2/20 0.47
GRM6 O15303 1/20 0.47
CYP1A2 P05177 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
BRAF P15056 1/20 0.46
ALDH1A1 P00352 3/20 0.45
PTPN1 P18031 1/20 0.44
TP53 P04637 2/20 0.44
HPGD P15428 1/20 0.44
CNR2 P34972 1/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.43
GAA P10253 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1490650 0.89 MAPT (0.52) LMNAKDM4EMAPTCYP1A2RAB9A
SCHEMBL1490520 0.83 MEN1 (0.49) LMNAMAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL1490393 0.83 MEN1 (0.49) LMNAMAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL3627300 0.81 MAPT (0.72) LMNAKDM4EMAPTTHRBPRKCZ
SCHEMBL3629109 0.81 MAPT (0.72) LMNAKDM4EMAPTTHRBPRKCZ
SCHEMBL1490585 0.78 KMT2A (0.47) LMNAMAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL1490509 0.77 KMT2A (0.55) LMNAKDM4EMAPTRAB9ASMN1; SMN2
SCHEMBL1490465 0.77 MAPT (0.52) LMNAKDM4EMAPTCYP1A2RAB9A
SCHEMBL1490525 0.77 MEN1 (0.64) LMNAKDM4EMAPTRAB9ASMN1; SMN2
SCHEMBL1490436 0.77 MAPT (0.52) LMNAKDM4EMAPTCYP1A2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 US disclosed
US-8618307-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2013-12-31 US disclosed
EP-2477982-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM Calcimedica, Inc. (US) 2012-07-25 EP disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 WO disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 LMNA 1306/4885KDM4E 4057/4885MAPT 1478/4885
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 LMNA 1306/4885KDM4E 4057/4885MAPT 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.